​

Prelude Therapeutics Ownership | Who Owns Prelude Therapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Prelude Therapeutics Ownership Summary


Prelude Therapeutics is owned by 52.96% institutional investors, 13.76% insiders, and 33.28% retail investors. Orbimed advisors is the largest institutional shareholder, holding 14.18% of PRLD shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 1.90% of its assets in Prelude Therapeutics shares.

PRLD Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockPrelude Therapeutics52.96%13.76%33.28%
SectorHealthcare Stocks 129.28%12.06%-41.34%
IndustryBiotech Stocks 181.42%11.67%-93.09%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Orbimed advisors10.91M14.18%$37.31M
Baker bros. advisors lp10.12M13.16%$34.62M
Boxer capital2.57M3.39%$9.79M
Affinity asset advisors2.60M2.64%$10.17M
Kynam capital management, lp1.59M2.07%$5.45M
Vanguard capital management1.90M1.93%$7.42M
Blackrock funding, inc. /de1.86M1.89%$7.26M
Vanguard group1.41M1.86%$4.10M
Blackrock1.07M1.41%$4.07M
Two sigma investments, lp923.63K1.20%$3.16M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Orbimed advisors10.91M0.74%$37.31M
Boxer capital2.57M0.52%$9.79M
Affinity asset advisors2.60M0.41%$10.17M
Kynam capital management, lp1.59M0.34%$5.45M
Sphera funds management558.34K0.30%$1.91M
Baker bros. advisors lp10.12M0.20%$34.62M
Spark investment management20.40K0.13%$79.76K
Integrated quantitative investments60.68K0.04%$237.25K
Entrypoint capital16.46K0.02%$64.34K
Shay capital100.00K0.01%$144.00K

Top Buyers

HolderShares% AssetsChange
Affinity asset advisors2.60M0.41%2.60M
Kynam capital management, lp1.59M0.34%803.68K
Sphera funds management558.34K0.30%435.59K
Vanguard group1.41M0.00%421.13K
Ubs group556.53K0.00%237.73K

Top Sellers

HolderShares% AssetsChange
Deerfield management company, l.p. (series c)---3.77M
Ecor1 capital---947.05K
Exoduspoint capital management, lp---921.62K
Avidity partners management lp---890.00K
Price t rowe associates inc /md/---755.96K

New Positions

HolderShares% AssetsChangeValue
Affinity asset advisors2.60M0.41%2.60M$10.17M
Citadel advisors124.38K0.00%124.38K$425.37K
Arrowstreet capital, limited partnership106.74K0.00%106.74K$417.36K
Integrated quantitative investments60.68K0.04%60.68K$237.25K
Empowered funds59.98K0.00%59.98K$234.51K

Sold Out

HolderChange
Nelson, van denburg & campbell wealth management group-1.00
Ifp advisors-1.00
Capital performance advisors llp-8.00
True wealth design-13.00
Highmark wealth management-50.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 2026908.43%52,108,0264.91%522.08%50-19.35%24166.67%
Jun 30, 20268348.21%49,667,03461.40%503.63%6293.75%9-25.00%
Mar 31, 202613-73.47%1,621,555-94.30%20.15%8-66.67%2-86.67%
Dec 31, 202526-42.22%4,054,360-85.07%50.42%12-20.00%9-52.63%
Sep 30, 202544-2.22%27,161,9481.82%352.90%15-11.76%18-14.29%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Total Stock Mkt Idx Inv1.51M1.90%577.82K
Vanguard Morn Total Stk Mkt Idx Investor1.51M1.90%577.82K
Vanguard MStar Total Stk Mkt Idx Invest1.51M1.90%-
Vanguard US Total Market Shares ETF720.43K1.31%-
iShares Russell 2000 ETF691.97K0.87%-
T. Rowe Price Health Sciences516.22K0.82%-40.53K
MFS New Discovery I327.70K0.60%-
Vanguard Institutional Extnd Mkt Idx Tr458.36K0.57%-
Biotech Growth Ord346.50K0.43%-
Fidelity Small Cap Index303.52K0.38%-

Recent Insider Transactions


DateNameRoleActivityValue
Apr 21, 2026Bonita David P Buy$7.50M
Apr 21, 2026Bonita David P Buy$5.00M
Apr 21, 2026ORBIMED ADVISORS LLC Buy$5.00M
Apr 21, 2026ORBIMED ADVISORS LLC Buy$7.50M
Apr 21, 2026BAKER BROS. ADVISORS LP Buy$213.77

Insider Transactions Trends


DateBuySell
2026 Q26-
2026 Q1--
2025 Q4--
2025 Q3--
2025 Q2--

PRLD Ownership FAQ


Who Owns Prelude Therapeutics?

Prelude Therapeutics shareholders are primarily institutional investors at 52.96%, followed by 13.76% insiders and 33.28% retail investors. The average institutional ownership in Prelude Therapeutics's industry, Biotech Stocks , is 181.42%, which Prelude Therapeutics falls below.

Who owns the most shares of Prelude Therapeutics?

Prelude Therapeutics’s largest shareholders are Orbimed advisors (10.91M shares, 14.18%), Baker bros. advisors lp (10.12M shares, 13.16%), and Boxer capital (2.57M shares, 3.39%). Together, they hold 30.72% of Prelude Therapeutics’s total shares outstanding.

Does Blackrock own Prelude Therapeutics?

Yes, BlackRock owns 1.41% of Prelude Therapeutics, totaling 1.07M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 4.07M$. In the last quarter, BlackRock decreased its holdings by -28.558K shares, a -2.60% change.

Who is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested?

Orbimed advisors is Prelude Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.74% of its assets in 10.91M Prelude Therapeutics shares, valued at 37.31M$.

Who is the top mutual fund holder of Prelude Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of Prelude Therapeutics shares, with 1.90% of its total shares outstanding invested in 1.51M Prelude Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools